Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. GNK
7. HTFL
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)

Argus Reiterates Buy Rating on Moderna (MRNA), 'Discounted price offers buying opportunity'

June 9, 2022 11:09 AM EDT

Argus analyst John Eade reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).

The analyst comments "We are maintaining our BUY rating on Focus List selection Moderna Inc. (NYSE: MRNA). The company develops therapeutics and... More